The federal government is appointing members to an implementation advisory group to support the launch of its national strategy for drugs for rare diseases.

The members from Canada’s private payer community include: Stephen Frank, president and chief executive officer of the Canadian Life and Health Insurance Association; Joanne Jung, Canadian pharmacy and clinical practice leader at WTW; and Gary Walters, chief actuary at GroupHEALTH Benefits Solutions.

Read: An update on Canada’s national strategy for drugs for rare diseases

The group — which also includes patients, caregivers and clinicians — will provide advice to Health Canada and other health-care partners on the implementation of the strategy and be a forum to exchange information and best practices on drugs for rare diseases, according to a press release. It also noted the group may invite external participation to support specific discussions and will also host an open town hall twice annually to share its progress.